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Sir,
I read with great satisfaction and enthusiasm the review
article by Professor Montagna, ‘‘The primary headaches:
genetics, epigenetics and a behavioural genetic model [1].’’
He presents a detailed outline of genetic studies in primary
headaches, mostly migraine, and at the same time discusses
the limitations associated with each of the approaches as
mirrored by the inconsistent results. In addition, a com-
prehensive hypothesis on migraine pathophysiology,
incorporating both the Darwinian perspective and recent
advances in epigenetics, is presented. This is satisfying in
two ways. First, it helps to understand why many of the
results are controversial. Most importantly he calls our
attention to something we all know: ‘migraine’ is a col-
lective term for a set of symptoms, as defined by the
International Headache Society [2]. This etiological het-
erogeneity is the main obstacle hampering genetic studies
and any small or moderate genetic effect, that may be
important for a subgroup of migraines of the same origin
(same underlying syndrome or disease), will inevitably be
diluted when we look at all migraines. Furthermore, envi-
ronmental aspects (nutrients, living conditions, etc., with
the potential to exert epigenetic changes) have so far been
disregarded in genetic studies. Second, this novel hypoth-
esis on migraine pathophysiology incorporates existing
knowledge into a new, more complex framework, rather
than refuting prior studies. This encourages continuing to
search for the origin of primary headaches.
Epigenetics refers to the heritability of traits not attrib-
utable to a change in DNA sequence. Two common
mechanisms are DNA methylation and post-translational
histone modification [3]. Although a relatively young
research branch, tremendous progress has been made in
elucidating how, e.g., DNA methylation regulates gene
expression and how that impacts disease susceptibility, in
particular cancerogenesis [3]. In addition, pharmacological
approaches to modify DNA methylation and, thus, gene
expression have come into focus recently [4]. In extension
to Professor Montagna’s ‘behavioural genetic model’ of
migraine and other primary headache disorders, I would
also like to suggest the idea of a epigenetic cause for
medication response. In migraine abortive and preventive
drugs are effective in only about half of patients [5] and in
cluster headache subcutaneous sumatriptan is effective in
80% of patients at best [6, 7]. These phenomena may be
explained by functional gene variants [8]. However,
response to analgesics and triptans can also change over
time and depending on the frequency of usage (medication
overuse headache impairing effectiveness of abortive
medication). This cannot be explained by simple altera-
tions in the genetic code, but suggests epigenetic changes
at target molecules. Such a ‘pharmaco(epi-)genetic’ model
would acknowledge both DNA sequence variation and
methylation, etc., as determinants of drug treatment
response.
This article [1] fuels headache research enthusiasm.
Admittedly, the proportion epigenetics plays with regard to
disease causation and drug response is unknown and
epigenetics will unlikely provide answers to all open
questions in headache research. However, I consider this
‘behavioural genetic model’ a very valuable framework
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allowing for reconsideration of the pathophysiology and
pharmacogenetics of primary headaches.
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